Focus Partners Advisor Solutions’s Fate Therapeutics FATE Stock Holding History

Focus Partners Advisor Solutions’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.3K	Buy	+15,221	New	+$18.5K	﹤0.01%	1243

Other funds holding FATE

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Focus Partners Advisor Solutions's FATE Position: Q1 2026 in Review

Focus Partners Advisor Solutions opened a new position in Fate Therapeutics (FATE) in Q1 2026: 15,221 shares worth $18.3K. The stake represents ﹤0.01% of the portfolio and ranks #1243 among its holdings.

157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

Focus Partners Advisor Solutions held 15,221 shares of Fate Therapeutics worth $18.3K as of Q1 2026.
Fate Therapeutics was a new Focus Partners Advisor Solutions position in Q1 2026.
Fate Therapeutics made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #1243 holding.
157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.